^
Association details:
| Biomarker: | PD-L2 overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response
Published date:
02/02/2022
Excerpt:
We aimed to develop a new signature based on immune-related genes to predict prognosis and response to immune checkpoint inhibitors in patients with triple-negative breast cancer (TNBC)....PD-1, PD-L1, PD-L2 and CTLA4 gene expression was higher in the low-risk group, suggesting IPRS could predict the response to immune checkpoint inhibitors.
DOI:
10.2217/fon-2021-0600
